ROGER D. ROSSEN, M.D.; BRIAN C. BARNES, M.D.
Circulating tumor antigen-antibody complexes appear to have a role in modulating cell-mediated immune responses against autologous tumors (1, 2). The usual effect is to suppress or block lymphocyte transformation and the generation of tumor-specific cytotoxic lymphocytes (2, 3). New techniques that permit measurement of the low levels of immune complexes in body fluids now make possible testing of the hypothesis that measurement of immune complexes in sera of cancer patients may be useful in detecting the residual tumor, in staging cancer, and in estimating prognosis (4).
In various human malignant diseases, levels of immune complexes, as measured by the Clq
ROSSEN RD, BARNES BC. Measuring Serum Immune Complexes in Cancer. Ann Intern Med. ;88:570–571. doi: 10.7326/0003-4819-88-4-570
Download citation file:
Published: Ann Intern Med. 1978;88(4):570-571.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use